报价延迟最少15分钟:2026/04/21 20:01 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.71 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.28/-1.33
|
|
企业价值
123.79M
|
| 资产负债 |
|
每股账面净值
0.85
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.15M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO,formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity. |
